

- 版，行政院衛生署。
5. United States Pharmacopeial Convention, Inc. 2009. The United States Pharmacopeia 32, The National Formulary 27. United States Pharmacopeial Convention, Inc. Rockville, Md. U.S.A.
 6. The Directorate for the Quality of Medicines of the Council of Europe. 2007. European Pharmacopoeia 6.0. The Directorate for the Quality of Medicines of the Council of Europe, France.
 7. National Institute of Infectious Diseases. 2006. Minimum Requirements for Biological Products. National Institute of Infectious Diseases, Japan.

Survey on Batch Release of Vaccines and Toxoids in Taiwan During 2009

HUI-CHIA CHAN, HUEY-JEN DUH, CHANG-WEN CHI, JIA-HAO LI, YI-CHAO LIU, YU-HUI HUANG, JIA-CHUAN HSU, YI-CHEN YANG, DER-YUAN WANG AND CHI-FANG LO

Division of Research and Analysis

ABSTRACT

This report presents the results of batch release of imported and domestic vaccines and toxoids during the period from January 1st to December 31st of 2009. Twenty four items and 2,968 tests were performed to analyze 200 batches which included 16,180,619 doses totally. The result of all complied with the Chinese pharmacopoeia and other regulations. These 200 batches of vaccines and toxoids belong to 34 licenses held individually by 8 vaccine companies. Forty two point one percent doses are domestic and 57.9% are imported. The number of certified batches and doses from Adimmune Corporation were the highest. In 16,180,619 doses of vaccines and toxoids, 26.9% doses are for bacteria, 69.5% for virus, and 3.6% for both virus and bacteria. Top 3 by batches are Influenza vaccines, tetanus toxoids and JE vaccines in order. Top 3 by dosages are Influenza vaccines, tetanus toxoids and HepB vaccines in order. Sixty two batches of 6,736,163 doses of influenza vaccines were certified in 2009.

Key words: vaccine, toxoid, batch release